These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 31488371)
21. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit. Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111 [TBL] [Abstract][Full Text] [Related]
22. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. Chow T; Kereiakes DJ; Bartone C; Booth T; Schloss EJ; Waller T; Chung E; Menon S; Nallamothu BK; Chan PS J Am Coll Cardiol; 2007 Jan; 49(1):50-8. PubMed ID: 17207722 [TBL] [Abstract][Full Text] [Related]
23. Cluster Randomized Trial Examining the Impact of Automated Best Practice Alert on Rates of Implantable Defibrillator Therapy. Lee J; Szeto L; Pasupula DK; Hussain A; Waheed A; Adhikari S; Sharbaugh M; Thoma F; Althouse AD; Fischer G; Lee JS; Saba S Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005024. PubMed ID: 31181957 [TBL] [Abstract][Full Text] [Related]
25. The effect of revascularization on mortality and risk of ventricular arrhythmia in patients with ischemic cardiomyopathy. Alkharaza A; Al-Harbi M; El-Sokkari I; Doucette S; MacIntyre C; Gray C; Abdelwahab A; Sapp JL; Gardner M; Parkash R BMC Cardiovasc Disord; 2020 Oct; 20(1):455. PubMed ID: 33087069 [TBL] [Abstract][Full Text] [Related]
33. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy. Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215 [TBL] [Abstract][Full Text] [Related]
34. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Theuns DA; Smith T; Hunink MG; Bardy GH; Jordaens L Europace; 2010 Nov; 12(11):1564-70. PubMed ID: 20974768 [TBL] [Abstract][Full Text] [Related]
36. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. Pathak RK; Sanders P; Deo R Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440 [TBL] [Abstract][Full Text] [Related]
38. Screening and risk evaluation for sudden cardiac death in ischaemic and non-ischaemic cardiomyopathy: results of the European Heart Rhythm Association survey. Proclemer A; Lewalter T; Bongiorni MG; Svendsen JH; Pison L; Lundqvist CB; Europace; 2013 Jul; 15(7):1059-62. PubMed ID: 23794672 [TBL] [Abstract][Full Text] [Related]
39. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442 [TBL] [Abstract][Full Text] [Related]